Stephen L. Huhn
Equibles does not estimate personal net worth.
Get an email with a short summary when Contineum Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CTNM alertsAbout Stephen L. Huhn
The proxy statement of Contineum Therapeutics, Inc. reports total compensation of $2,121,674 for Stephen L. Huhn in fiscal 2024, including a base salary of $485,403. Contineum Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Contineum Therapeutics, Inc. includes Carmine N. Stengone (CEO and Board Member), Peter T. Slover (CFO), John S. Healy (General Counsel) and 7 others.
Affiliation history
-
Contineum Therapeutics, Inc. (CTNM)
Proxy statement
Current
Company network
Leadership on record at Contineum Therapeutics, Inc.
- Carmine N. Stengone CEO, Board Member
- Peter T. Slover CFO
- John S. Healy General Counsel
- Diego Miralles Board Member
- Diego Miralles, M.D. Board Member
- Lori M. Lyons-Williams Board Member
- Olivia Ware Board Member
- Sarah Boyce Board Member
- Todd Brady Board Member
- Troy Ignelzi Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Contineum Therapeutics, Inc. (CTNM) | Former Chief Medical Officer and Senior Vice President of Clinical Development | $485,403 | $2,121,674 |
Recent activity
No call appearances or filed executive changes recorded yet.